of disorders associated with RS can broadly be divided into clonal hematological and nonclonal conditions (Figure 2 ), summarized as follows.
| Nonclonal sideroblastic anemias
These are inherited or acquired, nonclonal conditions that give rise to BM RS. Acquired conditions include excess alcohol use, copper deficiency, lead and zinc toxicity, and drugs such as isoniazid, chloramphenicol, penicillamine and linezolid (Table 1) . 3, 4 Genetically defined congenital sideroblastic anemias can be attributed to mutations in 1 of 3 mitochondrial pathways: heme synthesis, iron-sulfur cluster biogenesis and protein synthesis, or, rarely, a mutation in a protein involved in mitochondrial respiration itself. 8 The most common CSA is the X-linked sideroblastic anemia (XLSA) occurring secondary to heterogeneous, usually missense substitutions of conserved amino acids in the delta-aminolevulinate synthase 2 gene (ALAS2) 9 ; a gene encoding the first enzyme of the heme biosynthetic pathway. The activity of ALAS2 is pyridoxal 5-phosphate-dependant, with mutations that decrease the binding of the pyridoxal phosphate cofactor accounting for the pyridoxine responsiveness seen in some patients. Affected individuals usually have a microcytic hypochromic anemia and then eventually go on to develop signs and symptoms of iron overload (hemosiderosis). 3 Loss of function mutations in SLC25A38 have been shown to cause a sideroblastic anemia (SA) similar to XLSA, but with an autosomal recessive inheritance. 10 XLSA with ataxia is an inherited disorder associated with SA and nonprogressive spinocerebellar ataxia (cerebellar hypoplasia), secondary to mutations involving the ATP-binding cassette sub-family B member 7 (ABCB7). 11 Similarly, mutations involving glutaredoxin-5 (GLRX5), a gene that encodes a mitochondrial protein involved in iron-sulfur cluster biogenesis can give rise to CSA. 12 Recently, a recurring mutation in NDUFB11 (nuclear-encoded mitochondrial complex I protein) essential for mitochondrial oxidative phosphorylation was identified in 5 individuals from 4 families with variably syndromic, normocytic CSA. 8 Additional rare causes of CSA have been outlined in Table 1 and include mitochondrial deletion syndromes (more common in pediatric patients). Gene sequencing, including mitochondrial DNA sequencing and the establishment of heteroplasmy are becoming more accessible, leading to the availability of better diagnostic tests for these conditions.
| Clonal sideroblastic anemias
Two clonal myeloid disorders characteristically associated with anemia
and BM RS include RARS (now referred to as MDS-RS-single lineage dysplasia) and RARS-T (now referred to as MDS/MPN-RS-T). 2,13 The
World Health Organization (WHO) criteria for the diagnosis of MDS-RS used to necessitate the presence of ≥15% BM RS 1 , a criterion that was thought to be arbitrary and one without prognostic relevance. 14 In a study with 200 MDS patients without excess blasts and with ≥1% RS, the impact of RS% was assessed both as a continuous and categorical variable: <5% (n = 56), 5%-14% (n = 32), 15%-50% (n = 79), and >50%
(n = 33). 14 RS% correlated (P < .05) directly with age, platelet count, transfusion dependency, BM cellularity, and mutant SF3B1 and inversely with hemoglobin level, multilineage dysplasia, and high-risk karyotype. Neither univariate nor multivariable analysis showed significant effect for RS% on overall (OS) or leukemia-free survival (LFS), suggesting the limited prognostic value of quantifying BM RS. 14, 15 Based on this, the revised 2016 WHO criteria now allow for the diagnosis of MDS-RS with ≥5% BM RS, in the presence of SF3B1 mutations. 2 The number of RS required for a diagnosis of MDS/MPN-RS-T (≥15%) is not altered by the presence or absence of SF3B1 mutations. (Table 2) . 19, 20 Among these, SF3B1 (splicing factor 3B subunit 1) mutations were most common in patients with MDS-RS. 15, 19, 20 The SF3B1
protein is a core component of the U2 snRNP, which binds to the branch site, thereby base pairing with the intron RNA; a critical process during RNA splicing ( Figure 3 
No
Consider congenital sideroblastic anemias 108 months, with a very low risk for LT (<2%). 15, 38, 39 In a recent study, there was no difference in survival seen between MDS-RS-MLD and MDS-MLD, with the only independent prognosticators adversely impacting survival being thrombocytopenia and the presence of ASXL1 mutations. 13 
| Risk-adapted therapy
The management of patients with MDS-RS involves supportive care strategies outlined for lower-risk MDS patients and includes the use of erythropoiesis stimulating agents (ESA), transfusional supportive care and iron chelation therapy where applicable ( Figure 4 ).
40,41
Management of anemia 51 In a recent Mayo Clinic MDS study (n = 357), lenalidomide responses were more likely to occur in the presence of SF3B1 mutations (56% vs 27%, P = .04) and in the absence of ASXL1 and U2AF1 mutations and a high risk karyotype. 52 Sotatercept (ACE-011) and Luspatercept (ACE-536) are soluble fusion proteins that inhibit molecules in the TGF-β (transforming growth factor) superfamily, increasing hemoglobin levels by targeting a pathway fundamentally distinct from EPO. 53 The MEDALIST trial was a phase III, randomized, double-blind, placebo controlled study, assessing the efficacy of luspatercept vs placebo in lower-risk patients with MDS-RS who were refractory/intolerant or ineligible for ESA (EPO level >200 U/L) and were RBC-TD (≥2 units of RBC in 8 weeks). 54 One hundred and fifty-three patients received luspatercept at 1 mg/kg S.C. every 21 days, while 71 patients received placebo. The primary end point of RBC-TI ≥ 8 weeks was achieved in 58 (37.9%) patients in the luspatercept arm vs 10 (13.2%) in the placebo arm (P < .0001), whereas RBC-TI ≥12 weeks (weeks 1-48 of treatment) was achieved in 51 (33.3%) in the luspatercept arm and 9(11.8%) in the placebo arm (P = .0003). Importantly, the drug was well tolerated and there was no evidence for disease progression on therapy. 54 Similarly, imetelstat, a novel telomerase inhibitor has shown encouraging activity in lower risk, treatment naïve MDS patients that are RBC-TD. 
Iron chelation therapy
The indolent nature of MDS-RS, coupled with infective erythropoiesis and RBC-TD, can result in iron overload. 58 The iron status can be monitored noninvasively by measuring serum ferritin levels, transferrin saturation and by the utilization of T2* MRI (magnetic resonance imaging) scans. 58, 59 Increased serum ferritin levels in MDS can be secondary to TD, cancer-associated inflammation (acute phase reactant), and liver disease. [60] [61] [62] Each of these comorbidities are prognostically detrimental and it is unclear if iron overload, or for that matter an elevated ferritin level, per se contribute to mortality and morbidity. [60] [61] [62] Data suggesting hemosiderosis-related causes of death in MDS are scant and are limited to case reports. In a retrospective study of 126 MDS-RS patients, independent prognosticators for survival included, IPSS (P < .0001) categories and red cell TD at diagnosis (P = .001), but not the number of red cell units transfused during the disease course (P = .17). 60 There were no correlations between survival and serum ferritin level, measured either at diagnosis or during follow-up. Similarly, there was no difference in survival when patients were stratified by serum ferritin levels of < or ≥1000 ng/mL at diagnosis or peak serum ferritin levels of <1000, 1000-5000, or > 5000 ng/mL during follow-up. 60 Similarly, in 88 patients with WHO defined MDS with isolated del(5q), serum ferritin levels did not impact survival and with a median OS of 66 months, with 66% deaths documented at last follow-up, there were no deaths attributed to iron overload. 63 A recent prospective study also found no impact of elevated liver iron content, as measured by MRI scans, on post-allogeneic hematopoietic stem cell transplantation (HSCT) survival and outcomes. 64 Additionally, iron chelation agents such as desferrioxamine (parenteral), deferiprone and deferasirox (both oral) are expensive and are associated with side effects. 65 Desferrioxamine has been associated with deafness and visual side effects, 59 deferiprone with gastrointestinal (GI) side effects and agranulocytosis, 66 and deferasirox with renal failure, liver failure, cytopenias, and GI side effects. 67 The use of iron chelation therapy in MDS-RS awaits rigorous prospective evaluation and until this can be established, its routine use cannot be recommended.
Hypomethylating agent therapy
The upfront use of hypomethylating agents (HMA) such as 72 The OS response rate was 70% with DAC vs 49% with AZA (P = .03) and the RBC-TI rates were 32% and 16% (P = .2), respectively. 72 This trial provides us with the first prospective randomized comparison between azacitidine (AZA) and decitabine (DAC), albeit at lower doses and in lower-risk MDS.
Allogeneic stem cell transplantation
Allogeneic HSCT is the only curative strategy for patients with MDS.
This modality however is fraught with complications such as acute and chronic graft vs host disease (GVHD) and nonrelapse mortality (NRM). Seminal studies have shown no benefit for upfront allo-HSCT for lower-risk MDS patients, regardless of a myeloablative, 73 or a reduced intensity conditioning (RIC) strategy. 74 Cutler et al. demonstrated that for patients with lower-risk MDS, delayed myeloablative allo-HSCT was associated with maximum life expectancy. 73 In this study, the median OS of patients with IPSS low and intermediate-1 MDS were 141.1 and 62.9 months with nontransplant management, while these numbers decreased to 40.2 and 20.5 months with early transplant strategies. 73 In addition, adjustment for quality of life did not change the preferred treatment strategy. In this study 16% of patients in the nontransplant group and approximately 5% in the transplant group had a morphological diagnosis of MDS-RS-SLD. 73 Similarly, in de novo lower-risk MDS patients with ages between 60-70 years, OS was better with nontransplant strategies (77 months), in comparison to a RIC allo-HSCT (38 months). 74 Once again in this cohort quality-adjusted life expectancy did not alter preferred treatment strategy. In the non-transplant group, the lowerrisk MDS patients received ESA and supportive care, while the higher risk patients received HMA. PDGFRB, FGFR1 and the PCM1-JAK2 rearrangements, and the absence of t(3;3)(q21q26), inv(3)(q21q26), or del(5q). 2 In the differential diagnosis, it is important to exclude patients with ET or reactive thrombocytosis associated with BM RS. The median age for presentation usually ranges from 71 to 75 years and approximately 80% of patients do not have detectable clonal cytogenetic abnormalities. [75] [76] [77] Other entities included in the MDS/MPN overlap syndromes are:
CMML, juvenile myelomonocytic leukemia, atypical CML, and MDS/MPN-unclassifiable. 78 
| Mutations and Prognosis in MDS/MPN-RS-T
Gene mutations encountered in patients with MDS/MPN-RS-T include;
DNMT3A (~15%), and SETBP1 (~10%). 76, 77 In a recent European study (n = 92), gene mutations detected included: spliceosome components -SF3B1 90%, SRSF2 6.7%, U2AF1 5.3%, ZRSR2 2.7%; signaling pathways -JAK2V617F 57%, MPL 2.7%, CBL 4%; epigenetic regulators -ASXL1 15%, TET2 25%, EZH2 7%, DNMT3A 15%, IDH2 4%; and transcription regulators -ETV6 2.7%, RUNX1 1.3%. 77 Approximately 50% of patients harbored both the JAK2V617F and SF3B1 mutations. Conversely, most of the SF3B1wt patients had JAK2V617F and ASXL1 mutations. 77 In a Mayo Clinic study, 94% of patients had ≥1 mutations; common mutations being: SF3B1 85%, JAK2V617F 33%, ASXL1 29%, DNMT3A 13%, SETBP1 13%, and TET2 10%. 76 In a multivariable survival analysis, (n = 82), anemia (P = .02), and abnormal karyotype (P = .01) were independently prognostic for inferior survival. In patients with NGS information (n = 48), univariate analysis showed association between poor survival and presence of SETBP1 (P = .04) or ASXL1 (P = .08) mutations whereas the absence of these mutations (ASXL1 wildtype /SETBP1 wildtype ) was favorable (P = .04); the number of concurrent mutations did not provide additional prognostication (P = .3). 76 This resulted in a hazard ratio-weighted prognostic model, with 2 points for an abnormal karyotype, 1 point for either ASXL1
and/or SETBP1 mutations, and 1 point for a HB level < 10 g/dL, which effectively stratified patients into three risk categories; low (0 points), intermediate (1 point) and high (≥2 points), with median survivals of 80, 42, and 11 months, respectively (P = .01) ( Figure 5A ). 76 Mutations in exon 9 of the calreticulin gene (CALR) have been reported as mutually exclusive of JAK2 and MPL mutations and can be seen in 67%-71% of ET and 56%-88% of PMF patients with wild-type JAK2 or MPL. 79 However, unlike in MPN, MPL (1%-3%) and CALR (0%-3%) mutations are infrequent in MDS/MPN-RS-T. 76, 77, 79 In a large study comparing patients with MDS-RS, MDS/MPN-RS-T, and ET, patients with MDS/MPN-RS-T were found to have a better median OS than MDS-RS-SLD (76 months vs 63 months), and an inferior OS in comparison to patients with ET (76 months vs 117 months). 27 Importantly there was no difference in survival noted regardless of the JAK2 mutation status or the platelet threshold (> or < 600 × 10(9)/L). 27 There was no difference in supportive care, 
| Thrombosis in MDS/MPN-RS-T
The frequency of thrombotic events in MDS/MPN-RS-T is thought to be similar to that of ET (3.6 vs 3.9/100 patient-years), but more frequent than MDS-RS (3.6 vs 0.9/100 patient-years). 27 In a prior study (n = 15), 6 of 10 (60%) patients with SF3B1 mutant RARS-T had thrombotic events; whereas there were no thrombotic events in SF3B1 wildtype patients. 21 In a recent Mayo Clinic study, at a median follow-up of whereas one patient developed portal vein thrombosis. 25 In univariate analysis, hemoglobin <10 g/dL (P = .008), BM RS % (P = .04), history of thrombosis (P = .02), and presence of SF3B1 mutations (P = .017) were associated with an inferior thrombosis-free survival (TFS). Age (P = .07),
JAK2 mutation status (P = .56), and CV risk factors (P = .95) did not have prognostic impact. Given the association between SF3B1 mutations and BM RS, in a multivariable model that included these two as covariates, only the presence of SF3B1 mutations retained prognostic significance (P = .02) ( Figure 5B ). The presence of SF3B1 mutation remained significant (P = .04) (hazard ratio 8.9; 95% confidence interval 1.1-4.5) when history of thrombosis (P = .12) or hemoglobin <10 g/dL (P = .14) was introduced into the multivariable model. Thrombotic events occurring at or prior to diagnosis (P = .53), thrombotic events occurring after diagnosis (P = .69), SF3B1 (P = .83), and JAK2V617F
(P = .4) mutational status, and CV risk factors (P = .05) did not impact OS. 25 Thus, unlike in ET, prior thrombotic events in MDS/MPN-RS-T do not impact OS. 25 The mechanism by which SF3B1 mutations might increase thrombotic predisposition in patients with MDS/MPN-RS-T requires further study.
| Risk-adapted therapy
Given that, until recently, RARS-T was considered a provisional entity teria. 80 There were no venous thromboembolic events noted. In a second case report, lenalidomide therapy was able to achieve a complete molecular remission in one patient with MDS/MPN-RS-T. 81 Clinical trials with newer agents such as luspatercept and the novel telomerase inhibitor imetelstat are either in conception phase, or are currently ongoing. 82 Similar to ET, patients with MDS/MPN-RS-T are at risk for vasomotor symptoms such as migraine headaches, palpitations, acral paresthesias, atypical chest pain, and erythromelalgia along with arterial and venous thrombosis. 25, 27 Some patients may also develop an acquired von Willebrand's disease, particularly in the presence of extreme thrombocytosis (>1000 × 10(9)/L), and are at risk for aspirin related bleeding. 83 Similar to ET, we risk stratify patients with MDS/MPN-RS-T (especially those with SF3B1 mutations) into two categories; low risk (0 factors) and high risk (1 or 2 factors), based on age >60 years and a prior thrombotic event ( Figure 6 ). 84 We believe (in the absence of extreme thrombocytosis) that low risk patients with MDS/MPN-RS-T benefit from low dose aspirin therapy (81-100 mg), with a reduction in the risk for arterial thrombosis and a significant reduction in microvascular/vasomotor symptoms. 85 Recent data suggest an added benefit for twice daily aspirin dosing in patients with ET, a finding that needs to be explored in MDS/MPN-RS-T. 86 Alternative antiplatelet agents such as clopidogrel, prasugrel, and ticagrelor are considered in the setting of aspirin resistance, aspirin hypersensitivity or the need for dual antiplatelet therapy.
The value of cytoreductive therapy in MDS/MPN-RS-T is uncertain and its use might exacerbate anemia, which is the most frequent disease complication in MDS/MPN-RS-T. We therefore avoid the use of cytoreductive drugs in patients with anemia unless compelled by the presence of multiple risk factors for thrombosis. 84 Our drug of choice, if cytoreductive therapy is indicated, is hydroxyurea, which has been the mainstay of cytoreductive therapy, with randomized data in patients with ET demonstrating a significant reduction in thrombotic events. In a randomized study, after 27 months follow-up, thrombotic events were seen in 3.6% of ET patients on hydroxyurea and in 24% of patients in the control arm. 87 Alternate cytoreductive agents that we consider in the setting of hydroxyurea failure, refractoriness or intolerance, include; lenalidomide, interferon alpha, or busulfan. 84 Two recent studies of pegylated INF-α (90 μg SC weekly) in PV and ET reported hematologic remissions of 80% accompanied by decreases in JAK2V617F allele burden (complete molecular remission rate of 5%-10%). 88, 89 In one of the two studies, 77 cases were evaluable after a median follow-up of 21 months and 76% and 70% of patients with ET or PV, respectively, achieved a complete hematologic remission, mostly in the first 3 months; side effects were recorded in 96% of the patients and 22% had discontinued treatment. 89 A small study of busulfan in 36 patients with ET demonstrated safety and efficacy of the agent, without an increase in LT rates. 90 In the setting of extreme thrombocytosis, the diagnosis of acquired von Willebrand's disease should be evaluated for, using the ristocetin cofactor activity and the von Willebrand's factor multimer analysis. 84 Affected patients demonstrate an improvement in bleeding parameters after a reduction in the platelet count is achieved with cytoreductive agents.
Similar to lower-risk MDS and MPN patients, allo-HSCT is reserved for patients with refractory cytopenias or progressive disease. The risks of allo-HSCT namely, acute and chronic GVHD and the NRM currently limit the upfront use of this strategy for affected patients. 
